Investor Relations

Development Pipeline

Publicly funded programs

KMUi-Biomedicine-1: Development and preclinical qualification of novel periodontitis therapeutics for clinical application (ParoPaste) - Research and preclinical qualification of novel periodontitis therapeutics in proof-of-concept models and regulatory preparation for clinical application

Alternative metal binding groups in drugs for the treatment of periodontitis - AMePA

Controlled release drug delivery systems of innovative and selective drug molecules for the treatment of bacterial infectious diseases of the periodontum – ParoStop

Profiling inhibitors of bacterial glutaminyl cyclases as drug prototypes of novel periodontal therapeutics - PInParo

Awards

Investments